FCGR3A and neoplasm: Several studies have reported a correlation between clinical response and polymorphisms of Fc gamma receptor IIIa (FcγR3A, or CD16A) on NK cells, which recognizes the Fc portion of mAbs mediating ADCC as trastuzumab, bound to the tumor cells (8).